For example, NF2 mutations have been implicated in multiple cancers including malignant mesothelioma, meningioma, and schwannomas and it was found that YAP/TEAD pathway inhibition blocked growth and survival of these NF2-deficient tumors (31–36). A comprehensive analysis of over 10,000 cancer patient samples from The Cancer Genome Atlas revealed that over 30% of samples carried genetic alterations in core components of the Hippo pathway (29). This evidence concerns the gene NF2 and meningioma.